Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lung Neoplasms × Photochemotherapy × Clear all

Phase

Phase NA 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Cholangiocarcinoma 2 Rectal Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Lung Neoplasms 1 Digestive System Diseases 1 Constriction, Pathologic 1 Carcinoma 1 Biliary Tract Diseases 1 Bile Duct Neoplasms 1 Bile Duct Diseases 1 Barrett Esophagus 1 Adenocarcinoma 1

Interventions

Cisplatin 6 Pemetrexed 5 Carboplatin 5 Paclitaxel 4 pembrolizumab 3 Magnetic Resonance Spectroscopy 3 Docetaxel 3 Radiotherapy 2 Leucovorin 2 Gemcitabine 2 Erlotinib Hydrochloride 2 Dexamethasone 2 oblimersen 1 maimendongtang 1 endostar protein 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 cemiplimab 1 cediranib 1 auricularum 1 aumolertinib 1 anamorelin 1 Vitamin B 12 1 Vinorelbine 1 Specimen Handling 1 Sevoflurane 1 SR 48692 1 Rocuronium 1 Ramucirumab 1 Radiotherapy, Intensity-Modulated 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03346304 2019-02-01

PEARL

University College, London

Phase 2/3 Withdrawn

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡